Method for analyzing and detecting ridexamphetamine dimesylate enantiomer and application thereof
Through derivatization, dextamphetamine dimethic acid and its enantiomers have ultraviolet absorption characteristics, and normal-phase high-performance liquid chromatography detection has solved the problem that the prior art cannot effectively detect dextamphetamine dimethic acid pairs. The problem of enantiomers has achieved controllability of drug quality and guidance on formulation development.
Patent Information
- Application Number
- CN202310552796.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
Existing analytical technologies cannot effectively detect dextamphetamine dimethanesulfonate and its enantiomers, making it difficult to control impurities during the life cycle of the drug and affect the quality of the drug.
Dexamphetamine dimethanesulfonate and its enantiomers have ultraviolet absorption characteristics through derivatization method, and normal phase high performance liquid chromatography is used for detection and analysis, and appropriate chromatographic conditions are selected to achieve their separation and quantitative analysis.
The simple, rapid and accurate detection of dextamphetamine p-dimethylate and its enantiomers was achieved, ensuring the controllability of drug quality, and guiding the development of synthesis processes and formulations.
Smart Images

Figure CN119000896A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of drug analysis technology, and in particular to an analysis method for enantiomers in lisdexamfetamine dimesylate and its application. Background Art
[0002] Lisdexamfetamine dimesylate is chemically named ((2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimesylate) and its molecular formula is C 17 H 33 N3O7S2, CAS registration number 608137-33-3, chemical structure is as follows:
[0003]
[0004] Lisexamfetamine dimesylate is an amphetamine derivative developed by Shire Biopharmaceuticals and New River Pharmaceutical Inc. on February 23, 2007. It was first marketed in the United States under the trade name Vyvanse. It is an oral capsule for the treatment of attention-deficit / hyperactivity disorder (ADHD) in children. Lisexamfetamine dimesylate is currently the only stimulant approved for maintenance treatment of all ADHD patients over the age of 6. In January 2015, the FDA approved the drug as the first and only drug for the treatment of moderate to severe binge eating disorder in adults.
[0005] Lisamfetamine has two chiral carbon centers, of which (R)-2,6-diamino-N-((R)-1-phenylpropan-2-yl)hexanamide is its enantiomer, which is also a potential impurity that needs to be urgently controlled in raw materials and their preparations. The specific structure is shown in the following formula:
[0006]
[0007] In view of the fact that the quality standard of rexroxamphetamine dimesylate capsules is not included in the pharmacopoeias of various countries at present, and the analytical method of the above enantiomers of the product has not been recorded in the literature, and due to the different structures and physicochemical properties of different drugs and their isomers, it is impossible to determine whether the analytical detection of rexroxamphetamine dimesylate and its isomers can use the existing analytical detection technology, but the control of impurities plays a vital role in the entire life cycle of the drug. Therefore, it is urgent to establish an easy-to-operate analytical method for the above enantiomers of rexroxamphetamine dimesylate, so as to better promote the research and development of the drug and ensure the quality control of the product. Summary of the invention
[0008] In order to achieve the above-mentioned purpose of the invention, the present application provides a method for analyzing the enantiomers of rexroxamphetamine dimethanesulfonate. Since rexroxamphetamine dimethanesulfonate and its enantiomers have no ultraviolet absorption, a derivatization method is used to enhance their ultraviolet absorption, and then normal phase high performance liquid chromatography is used for detection and analysis. By selecting specific chromatographic conditions, rexroxamphetamine dimethanesulfonate and its enantiomers can be simply, quickly and accurately analyzed and detected, thereby ensuring the quality controllable of rexroxamphetamine dimethanesulfonate and its preparations.
[0009] The first aspect of the present application provides a method for detecting enantiomers in lisdexamfetamine dimesylate, the method comprising the following steps:
[0010] i) subjecting lisdexamfetamine dimethanesulfonate and its enantiomer to a derivatization reaction with a derivatization agent to obtain a derivatization product of lisdexamfetamine dimethanesulfonate and its enantiomer;
[0011] ii) using normal phase high performance liquid chromatography to detect and analyze the derivatized product in step i), and to detect and separate the derivatized dimesylated lisdexamfetamine and its enantiomers.
[0012] In an exemplary embodiment, in step i), the derivatization reaction can be carried out as follows:
[0013] Adding lisdexamfetamine dimesylate and its enantiomers into a solvent, dissolving by ultrasonication and filtering;
[0014] Adding an alkaline regulator makes it alkaline;
[0015] Add a derivatization reagent to carry out a derivatization reaction.
[0016] After the reaction is completed, the mixture is cooled to room temperature to obtain a solution of a derivatized product of dimesylated amphetamine and its enantiomers.
[0017] In an exemplary embodiment, in step i), optionally, the solvent is methanol, and the concentration of the dimesylate lisdexamfetamine and its enantiomers is 10 mg / mL;
[0018] Optionally, the alkaline regulator is triethylamine or sodium hydroxide, preferably triethylamine; wherein 200 μl of the alkaline regulator is added to every 10 ml of the solution of lisdexamfetamine dimesylate and its enantiomers.
[0019] In an exemplary embodiment, in step i), optionally, the derivatization agent is a carboxylate, preferably di-tert-butyl dicarbonate; 250 μl or more of the derivatization agent is added to every 10 ml of the solution of lisdexamfetamine dimesylate and its enantiomers.
[0020] In an exemplary embodiment, in step i), preferably, the derivatization reaction can be heated in a water bath, wherein the reaction temperature is 40-60°C and the reaction time is more than 1 hour, preferably, the reaction temperature is 50°C and the reaction time is 1 hour.
[0021] In an exemplary embodiment, in step ii), the derivatized solution of lisdexamfetamine dimesylate and its enantiomers in step i) is injected into a normal phase high performance liquid chromatography, and the chromatogram is recorded; wherein the normal phase high performance liquid chromatography uses a chiral chromatographic column as a separation column, and the stationary phase of the chiral chromatographic column is a polysaccharide, and optionally, the stationary phase is amylose-tri-(3-chloro-5-methylphenylcarbamate) covalently bonded to the surface of silica gel.
[0022] In an exemplary embodiment, the chromatography column is CHIRALPAK IG, 4.6×250 mm; 5 μm.
[0023] In an exemplary embodiment, in step ii), optionally, the mobile phase in the normal phase HPLC column is a mixture of an organic solvent and an acid-base regulator, wherein the volume ratio of the organic solvent to the acid-base regulator is 100:(0.05-0.15), preferably, 100:0.1.
[0024] In an exemplary embodiment, optionally, the acid-base regulator is an organic acid, preferably trifluoroacetic acid.
[0025] In an exemplary embodiment, optionally, the organic solvent is a mixed solvent of n-hexane and lower alcohol, and the volume ratio is (85-90):(10-15), preferably, 90:10.
[0026] In an exemplary embodiment, optionally, the lower alcohol is selected from one or both of methanol and ethanol. Preferably, the lower alcohol is a combination of methanol and ethanol.
[0027] In an exemplary embodiment, the volume ratio of each component in the organic solvent is n-hexane: methanol: ethanol is 90: 2.5: 7.5.
[0028] In an exemplary embodiment, in step ii), optionally, other conditions of normal phase high performance liquid chromatography include: a wavelength range of 200 to 400 nm, preferably a wavelength of 210 nm;
[0029] The injection volume was 20 μL;
[0030] The flow rate is 1.0-1.2 mL / min, preferably, the flow rate is 1.1 mL / min;
[0031] The column temperature is 32°C-38°C, preferably 35°C;
[0032] Isocratic elution.
[0033] The second aspect of the present invention provides a method for detecting enantiomers in a rexroximate dimesylate preparation, comprising derivatizing the rexroximate preparation according to the above method, and using normal phase high performance liquid chromatography to perform qualitative and quantitative analysis of the enantiomers contained in the rexroximate preparation under the above chromatographic conditions.
[0034] In an exemplary embodiment, optionally, the rexroxamphetamine dimesylate preparation is a capsule preparation.
[0035] In an exemplary embodiment, the method comprises the following steps:
[0036] S100: Preparation of solution
[0037] S101: preparing reference substance solutions: preparing a stock solution of lisdexamfetamine dimesylate and a stock solution of a reference substance of its enantiomer, respectively, and subjecting them to derivatization reactions with derivatization reagents, respectively, to obtain a lisdexamfetamine dimesylate reference substance solution a1 and a reference substance solution a2 of its enantiomer;
[0038] S102: preparing a test solution: preparing a test stock solution of the dixamfetamine dimesylate preparation and subjecting it to a derivatization reaction with a derivatization reagent to obtain a test solution;
[0039] S103: Prepare a control solution: dilute the test solution in step S102 to obtain a control solution;
[0040] S200: Detection
[0041] Detect the reference solution a1 and a2 in step S101, the test solution in S102, and the reference solution in S103, and record the chromatograms;
[0042] S300: Analysis
[0043] Determine the retention time of lisdexamfetamine dimesylate and its enantiomer derivatized product according to the chromatogram in step S200;
[0044] The content of the enantiomer in the test sample was calculated by the self-control method based on the peak area of the derivatized product of the dimethoate enantiomer in the chromatograms of the test solution and the control solution.
[0045] In an exemplary embodiment, in step S101, the preparation method of the reference solution a1 of lisdexamfetamine dimesylate and the reference solution a2 of its enantiomer is as follows:
[0046] Rexrothricin dimethanesulfonate reference substance solution a1: The rexrothricin dimethanesulfonate reference substance is dissolved in a solvent to obtain a rexrothricin dimethanesulfonate reference substance stock solution, wherein the concentration of the rexrothricin dimethanesulfonate reference substance stock solution is 10 mg / mL; a portion of the rexrothricin dimethanesulfonate reference substance stock solution is transferred, an alkaline regulator is added until it becomes alkaline, and a derivatization reaction is carried out with a derivatization reagent to obtain the rexrothricin dimethanesulfonate reference substance solution a1; specifically, 5 mL of the rexrothricin dimethanesulfonate reference substance stock solution is transferred into a 100 mL conical flask with a bottle stopper, 100 μL of the alkaline regulator is added until it becomes alkaline, 125 μL of the derivatization reagent is added, the solution is sealed, and the solution is heated; after the reaction is completed, the solution is cooled to room temperature to obtain the solution;
[0047] Enantiomer reference substance solution a2: The rexrolide dimethanesulfonate enantiomer reference substance is dissolved in a solvent to obtain a rexrolide dimethanesulfonate enantiomer reference substance stock solution, wherein the concentration of the rexrolide dimethanesulfonate enantiomer reference substance stock solution is 1 mg / mL; a portion of the rexrolide dimethanesulfonate enantiomer reference substance stock solution is transferred, an alkaline regulator is added until it becomes alkaline, and a derivatization reaction is carried out with a derivatization reagent to obtain the rexrolide dimethanesulfonate enantiomer reference substance solution a2; specifically, 100 μL of the enantiomer reference substance stock solution is transferred into a 100-mL conical flask with a stopper and containing 5 mL of methanol, 100 μL of the alkaline regulator is added until it becomes alkaline, 125 μL of the derivatization reagent is added, the solution is sealed, and the solution is heated; after the reaction is completed, the solution is cooled to room temperature to obtain the solution.
[0048] In an exemplary embodiment, in step S102, the preparation method of the test solution is as follows:
[0049] The dixamfetamine dimethanesulfonate preparation is dissolved and filtered with a solvent, and the filtrate is taken as a test sample stock solution, wherein the concentration of the dixamfetamine dimethanesulfonate test sample stock solution is 10 mg / mL; a portion of the test sample stock solution is transferred, an alkaline regulator is added until it becomes alkaline, and a derivatization reaction is carried out with a derivatization reagent to obtain the test sample solution; specifically, the content of the dixamfetamine dimethanesulfonate capsule preparation (approximately equivalent to 200 mg of dixamfetamine dimethanesulfonate) is taken, 20 mL of methanol is added for ultrasonic dissolution, and the test sample stock solution is obtained by filtration; 10 mL of the test sample stock solution is accurately transferred into a 100 mL conical flask, 200 μL of an alkaline regulator is added until it becomes alkaline, 250 μL of a derivatization reagent is added, the flask is sealed, and heated. After the reaction is completed, the flask is cooled to room temperature to obtain the test sample solution.
[0050] In an exemplary embodiment, in step S103, the control solution is prepared as follows:
[0051] Take 100 μL of the test solution in step S102 into a 10 mL volumetric flask, add methanol to dilute to the scale, and shake well to obtain the control solution.
[0052] In an exemplary embodiment, in step S300, the calculation formula for the enantiomer content in the test sample is:
[0053]
[0054] Compared with the related art, this application has the following advantages:
[0055] Since both rexroamphetamine dimethanesulfonate and its enantiomers have no ultraviolet absorption, the present application adopts a derivatization method to enhance its ultraviolet absorption, and then performs detection and analysis by normal phase high performance liquid chromatography. By selecting specific chromatographic conditions, rexroamphetamine dimethanesulfonate and its enantiomers can be simply, quickly and accurately analyzed and detected, thereby ensuring that the quality of rexroamphetamine dimethanesulfonate and its preparations is controllable. The method of the present invention can be used to determine the content of the enantiomers in rexroamphetamine dimethanesulfonate, which plays a guiding role in the development of the synthesis process and related preparations, and is also helpful in formulating the quality standards for the raw materials.
[0056] Other features and advantages of the present application will be described in the following description, and partly become apparent from the description, or be understood by implementing the present application. Other advantages of the present application can be realized and obtained by the schemes described in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] The accompanying drawings are used to provide an understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.
[0058] Figure 1 HPLC spectrum of the chromatographic column CHIRALPAK IG in Example 1;
[0059] Figure 2 is the HPLC spectrum of the chromatographic column AY-H in Example 1;
[0060] Figure 3 This is the HPLC spectrum of the derivatized compound solution when the mobile phase 1 is used in Example 2;
[0061] Figure 4 This is the HPLC spectrum of the derivatized compound solution when mobile phase 2 is used in Example 2;
[0062] Figure 5 This is the HPLC spectrum of the derivatized compound solution when the mobile phase 3 is used in Example 2;
[0063] Figure 6 This is the UV absorption spectrum of lisdexamfetamine dimesylate before derivatization;
[0064] Figure 7 The full wavelength scanning HPLC spectrum of the derivatized product solution of dimethoate in Example 3;
[0065] Figure 8 This is the HPLC spectrum of the derivatized product solution in Example 4;
[0066] Fig. 9 The HPLC spectrum of the derivatization product of the dimethoate enantiomer of lisdexamfetamine in Example 5;
[0067] Fig.10 The blank solvent HPLC spectrum in Example 5;
[0068] Fig.11 The HPLC spectrum of the blank auxiliary material in Example 5;
[0069] Fig.12 The HPLC spectrum of the system suitability solution in Example 5;
[0070] Fig.13 This is the linear spectrum of Example 8. DETAILED DESCRIPTION
[0071] In order to make the purpose, technical solution and advantages of the present application more clear, the embodiments of the present invention will be described in detail below. It should be noted that the embodiments and features in the embodiments of the present application can be combined with each other arbitrarily without conflict.
[0072] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
[0073] Example 1 Chromatographic column screening
[0074] 1.1. Main technical parameters of HPLC
[0075] Instrument: Dinone U3000 liquid chromatograph
[0076] Column 1: CHIRALPAKIG, 4.6×250 mm; 5 μm
[0077] Column 2: AY-H, 4.6×250mm; 5μm
[0078] Mobile phase: n-hexane: methanol: ethanol: trifluoroacetic acid = 90: 2.5: 7.5: 0.1
[0079] Elution mode: isocratic elution;
[0080] Column temperature: 35°C;
[0081] Detection wavelength: 210nm;
[0082] Injection volume: 20 μL
[0083] Flow rate: 1.1 mL / min
[0084] 1.2 Detection and Analysis
[0085] Weigh 500 mg of rexroxamphetamine dimethanesulfonate and enantiomer reference substance, add 50 ml of methanol to dissolve, respectively obtain reference substance stock solutions, adjust the pH with sodium hydroxide solution, then add 1250 μL of derivatization reagent di-tert-butyl dicarbonate and 100 mL of extractant isopropyl acetate, respectively, stir the reaction at room temperature for 1 h, extract once, and obtain rexroxamphetamine dimethanesulfonate derivatization product and rexroxamphetamine dimethanesulfonate enantiomer derivatization product.
[0086] Take 200 mg of the above-mentioned dimethysulfonic acid lisdexamfetamine derivative product and 2 mg of its enantiomer derivative product, dissolve them in mobile phase to 20 mL respectively, inject the dimethysulfonic acid lisdexamfetamine derivative product solution and its enantiomer derivative product solution into a liquid chromatograph, record the chromatogram, and obtain the following: Figures 1-2 HPLC profile shown.
[0087] Conclusion: By analyzing the Figures 1-2 The HPLC spectrum shown shows that the response value of the enantiomer derivatization product is very low and cannot be completely separated when using chromatographic column 2 for detection and analysis, while the two can be completely separated when using chromatographic column 1 for detection and analysis. Therefore, the chromatographic column CHIRALPAK IG, 4.6×250mm; 5μm was selected.
[0088] Example 2 Chromatograms of derivative solutions under different mobile phases
[0089] 2.1. Main technical parameters of HPLC
[0090] Instrument: Dinone U3000 liquid chromatograph
[0091] Chromatographic column: CHIRALPAK IG, 4.6×250mm; 5μm
[0092] Mobile phase 1: n-hexane: ethanol: trifluoroacetic acid = 90: 10: 0.1
[0093] Mobile phase 2: n-hexane: methanol: ethanol: trifluoroacetic acid = 85: 5: 10: 0.1
[0094] Mobile phase 3: n-hexane: methanol: ethanol: trifluoroacetic acid = 90: 2.5: 7.5: 0.1
[0095] Column temperature: 35°C;
[0096] Detection wavelength: 210nm;
[0097] Injection volume: 20 μL
[0098] Flow rate: 1.1 mL / min
[0099] 2.2 Detection and Analysis
[0100] Weigh 50 mg of each of lisdexamfetamine dimesylate and enantiomer reference substance, add 5 ml of methanol to dissolve, respectively obtain reference substance stock solutions, adjust the pH with sodium hydroxide solution, then add 125 μL of derivatization reagent di-tert-butyl dicarbonate and 10 mL of extraction agent isopropyl acetate, respectively, stir at room temperature for 1 hour, extract once, take the derivatization product solution after extraction and inject it into liquid chromatograph for detection and analysis, and obtain the data results as shown in Table 1 and as shown in Table 2. Figures 3 to 5 HPLC chromatogram shown.
[0101] Table 1. Mobile phase screening test results
[0102] Project Name Mobile phase 1 Mobile phase 2 Mobile phase 3 Retention time of dimethoate derivatives of lisdexamfetamine 41.540 15.337 22.990 Retention time of enantiomer derivatives 21.626 9.969 14.147 Theoretical plate number of dimethoate lisdexamfetamine derivatives 1806 1319 1698 Theoretical plate number of enantiomer derivatives 2309 2208 2379 Separation 6.99 4.24 5.23
[0103] Combining Table 1 and Figures 3 to 5 From the test results, it can be seen that the derivative solutions under different mobile phases all meet the requirements of separation degree, all of which are greater than 4, and can achieve effective separation of dixamfetamine dimesylate and its enantiomers; the retention times of the three mobile phases are different, but all can complete the analysis and detection of the entire sample within 60 minutes.
[0104] Example 3 Wavelength Screening
[0105] 3.1. Main technical parameters of HPLC
[0106] Instrument: Dinone U3000 liquid chromatograph
[0107] Chromatographic column: CHIRALPAK IG, 4.6×250mm; 5μm
[0108] Mobile phase: n-hexane: methanol: ethanol: trifluoroacetic acid = 90: 2.5: 7.5: 0.1
[0109] Column temperature: 35°C;
[0110] Detection wavelength: 200~400nm;
[0111] Injection volume: 20 μL
[0112] Flow rate: 1.1 mL / min
[0113] 3.2 Detection and Analysis
[0114] Weigh an appropriate amount of the capsule contents (equivalent to 50 mg of lisdexamfetamine dimesylate), add 5 ml of methanol, adjust the pH with sodium hydroxide solution, then add 125 μL of the derivatization reagent di-tert-butyl dicarbonate and 10 mL of the extractant isopropyl acetate, react at room temperature with stirring for 1 hour, extract once, take the derivatization product solution after the above extraction and inject it into the liquid chromatograph for full wavelength scanning to obtain the following: Figure 7 HPLC chromatogram shown.
[0115] The full wavelength scanning spectrum showed that the derivatized product of dimethoate had the strongest absorption at 210 nm, and the baseline could meet the detection requirements. Finally, it was determined that the wavelength of 210 nm was selected as the final chromatographic condition.
[0116] Example 4 Derivatization Condition Screening
[0117] 4.1. Main technical parameters of HPLC
[0118] Instrument: Dinone U3000 liquid chromatograph
[0119] Chromatographic column: CHIRALPAK IG, 4.6×250mm; 5μm
[0120] Mobile phase: n-hexane: methanol: ethanol: trifluoroacetic acid = 90: 2.5: 7.5: 0.1
[0121] Elution mode: isocratic elution;
[0122] Column temperature: 35°C;
[0123] Detection wavelength: 210nm;
[0124] Injection volume: 20 μL
[0125] Flow rate: 1.1 mL / min
[0126] 4.2 Detection and Analysis
[0127] Solution preparation
[0128] 4.2.1 Stock solution of rexroxamphetamine dimethanesulfonate enantiomer reference substance: weigh 20 mg of rexroxamphetamine dimethanesulfonate enantiomer reference substance and place it in a 20 mL volumetric flask, add methanol to dissolve to volume, and shake well to obtain the stock solution of rexroxamphetamine dimethanesulfonate enantiomer reference substance.
[0129] Weigh the contents of the rexroximate dimethanesulfonate capsule (equivalent to approximately 200 mg of rexroximate dimethanesulfonate), add 20 mL of methanol, dissolve by ultrasonication, filter, take 5 mL of the filtrate, add 100 μL of the above-mentioned rexroximate dimethanesulfonate enantiomer reference substance stock solution, add triethylamine to adjust the pH to alkaline conditions, add 125 μL of di-tert-butyl dicarbonate, shake well, seal, and react in a 50°C water bath for 1 h to obtain a derivatized product solution.
[0130] 4.2.2 Similarly, take the contents of the rexroxamphetamine dimethanesulfonate capsule (equivalent to approximately 50 mg of rexroxamphetamine dimethanesulfonate), add 5 mL of methanol, add 100 μL of the rexroxamphetamine dimethanesulfonate enantiomer reference substance stock solution in 4.2.1, add sodium hydroxide solution to adjust the pH, then add 125 μL of the derivatization reagent di-tert-butyl dicarbonate and the extractant isopropyl acetate, and react at room temperature with stirring for 1 h to obtain the derivatization product solution.
[0131] 4.3 Detection and analysis
[0132] Take the two derivatization product solutions in 4.2.1 and 4.2.2 and inject them into the liquid chromatograph, record the chromatogram, and obtain the following: Figure 8 The HPLC profile is shown.
[0133] Conclusion: Comparative analysis of the above experimental processes shows that the HPLC spectra of the two derivatization products in 4.2.1 and 4.2.2 are consistent. However, compared with the method in 4.2.2 in which sodium hydroxide is used as a pH regulator and a derivatization reagent, di-tert-butyl dicarbonate and an extractant, isopropyl acetate are added to carry out the derivatization reaction, the method in 4.2.1 in which dimethoxypheneamine and its enantiomers are dissolved in methanol and methanol is used as the derivatization solvent is simpler to operate, the reaction is cleaner, there is no interference from excipients, and the derivatization reaction is carried out more completely in one phase.
[0134] Example 5 Specificity Test
[0135] 5.1. Main technical parameters of HPLC
[0136] Instrument: Agilent liquid chromatograph
[0137] Chromatographic column: CHIRALPAK IG, 4.6×250mm; 5μm
[0138] Mobile phase: n-hexane: methanol: ethanol: trifluoroacetic acid = 90: 2.5: 7.5: 0.1
[0139] Column temperature: 35°C;
[0140] Detection wavelength: 210nm;
[0141] Injection volume: 20 μL
[0142] Flow rate: 1.1 mL / min
[0143] 5.2 Detection and Analysis
[0144] 5.2.1 Rexrothimethanol dimethoxylamine enantiomer reference solution a2: Weigh 20 mg of rexrothimethanol dimethoxylamine enantiomer reference solution and place it in a 20 mL volumetric flask. Add methanol to dissolve and dilute to the mark to obtain the rexrothimethanol dimethoxylamine enantiomer reference solution. Take 100 μL of the rexrothimethanol dimethoxylamine enantiomer reference solution and place it in a 100 mL conical flask with a stopper and 5 mL of methanol. Add 100 μL of triethylamine to adjust the pH, then add 125 μL of the derivatization reagent di-tert-butyl dicarbonate, seal the bottle, and place it in a 50°C water bath to react for 1 h to obtain the rexrothimethanol dimethoxylamine enantiomer reference solution a2.
[0145] 5.2.2 Rexrothromide dimethanesulfonate reference substance solution a1: Weigh 200 mg of rexrothromide dimethanesulfonate reference substance, place it in a 20 mL volumetric flask, add methanol to dissolve and dilute to the mark to obtain the rexrothromide dimethanesulfonate reference substance stock solution; take 5 mL of the rexrothromide dimethanesulfonate reference substance stock solution and place it in a 100 mL conical flask with a stopper, add 100 μL of triethylamine to adjust the pH, then add 125 μL of the derivatization reagent di-tert-butyl dicarbonate, seal the bottle, and place it in a 50°C water bath to react for 1 hour to obtain the rexrothromide dimethanesulfonate reference substance solution a1.
[0146] 5.2.3 System suitability solution: Take 15 mL of the rexroxamphetamine dimethanesulfonate reference solution a in 5.2.2, add 100 μL of the rexroxamphetamine dimethanesulfonate enantiomer reference solution in 5.2.1, add 100 μL of triethylamine to adjust the pH, then add 125 μL of di-tert-butyl dicarbonate, shake well, seal, and place in a 50°C water bath to react for 1 hour to obtain the system suitability solution.
[0147] Take the above-mentioned saxamfetamine dimethanesulfonate reference substance solution a1, saxamfetamine dimethanesulfonate enantiomer reference substance solution a2, blank solvent, blank auxiliary material solution and system suitability solution and inject them into liquid chromatograph for analysis, record chromatogram, calculate separation, and obtain the data in Table 2 as follows and as Figures 9 to 12 HPLC chromatogram shown.
[0148] Table 2. Specificity results
[0149] Substance name Retention time / min Separation Enantiomeric derivatives 11.857 1.88 Lisexamfetamine dimesylate derivatives 17.652 NA
[0150] Conclusion: According to the chromatogram of the system suitability solution, the separation degree of the enantiomers of rexroxamphetamine dimesylate is greater than 1.5; the blank solvent and blank excipient solution have no interference with the main peak. This shows that this method has good specificity for detecting the enantiomers of rexroxamphetamine dimesylate.
[0151] Example 6 Precision Test
[0152] Chromatographic conditions are the same as in Example 5
[0153] 6.1 Repeatability test
[0154] 6.1.1 Test solution: Take 20 capsules of rexroxamphetamine dimethanesulfonate, accurately weigh the total weight, pour out the contents and weigh the total weight of the capsule shell, calculate the average filling amount, place the contents in a mortar for mixing, weigh an appropriate amount of powder (equivalent to 200 mg of rexroxamphetamine dimethanesulfonate), add 20 mL of methanol and ultrasonically dissolve, filter, and take the filtrate as the test solution stock solution; accurately transfer 5 mL of the test solution stock solution into a 100 mL conical flask, add 100 μL of the rexroxamphetamine dimethanesulfonate enantiomer reference solution in 5.2.1, add 100 μL of triethylamine to adjust the pH, shake well, then add 125 μL of di-tert-butyl dicarbonate, shake well, seal, and place in a 50°C water bath for reaction for 1 h to obtain the test solution.
[0155] 6.1.2 Control solution: Take 100 μL of the above test solution in a 10 mL volumetric flask, add methanol to dilute to the scale, and shake well to obtain the control solution.
[0156] Prepare 6 portions of the above test solution and the corresponding control solution in parallel, take 20 μL of each sample for analysis, record the peak area in the chromatogram, and use the self-control method to calculate the enantiomer content in the 6 portions of the test solution using the following formula. The results are shown in Table 3 below. The calculation formula is as follows:
[0157]
[0158] 6.2 Intermediate precision test
[0159] Take 5 mL of the test solution stock solution in 6.1.1 and place it in a conical flask with a stopper, add 100 μL of the dimethysulfonate enantiomer reference solution in 5.2.1, then add 100 μL of triethylamine to adjust the pH, add 125 μL of di-tert-butyl dicarbonate, shake well, seal, and react in a 50℃ water bath for 1 h to obtain the product.
[0160] Two analysts prepared the above 6 identical solutions and corresponding control solutions at different times and tested them on different instruments. Take 20 μL of each solution for injection analysis, record the peak area in the chromatogram, and use the self-control method to calculate the content of the enantiomer of dimethysulfonate lisdexamfetamine in the 6 solutions using the formula in 6.1. The data results are shown in Table 3 below.
[0161] Table 3. Repeatability and intermediate precision results
[0162]
[0163] Conclusion: The standard deviation of intermediate precision is 0.01% (n=12), and the absolute difference of 12 samples is less than 0.02%, which meets the requirements, indicating that the method has good precision.
[0164] Example 7 Stability Test
[0165] The instrument and chromatographic conditions were the same as in Example 5.
[0166] Take the test solution numbered 1 in Example 6.1 and the corresponding control solution and inject them once every 12 hours, inject them into the liquid chromatograph for detection and analysis, and record the peak area of the enantiomer derivative of dimethysulfonic acid lisdexamfetamine in the chromatogram of the test solution and the peak area of the main peak in the chromatogram of the control solution. The results are shown in Table 4:
[0167] Table 4. Stability results
[0168] time Peak area of enantiomer derivatives in the test solution The main peak area in the control solution 0h 6.653 38.025 12h 6.466 37.815 24h 6.456 38.236 36h 6.507 38.854 48h 6.664 39.292 60h 6.521 39.867 72h 6.748 40.596 84h 6.835 40.599 96h 8.210 40.927 Peak area average 6.784 39.357 RSD / % 8.2 3.1
[0169] Conclusion: The RSD of the peak area of the enantiomer derivative of dimethoate of lisdexamfetamine in the test solution was 8.2%, which met RSD≤10.0%, and the RSD of the peak area of the main peak in the control solution was 3.1%, which met RSD≤5.0%, indicating that the control solution and the test solution were stable within 96 hours at room temperature.
[0170] Example 8 Linearity Test
[0171] The instrument and chromatographic conditions were the same as in Example 5.
[0172] The enantiomer reference substance of lisdexamfetamine dimesylate was taken respectively to prepare methanol solutions of different concentrations, and the concentrations of each solution are shown in Table 5. Take 10 mL of each of the above solutions of different concentrations, add 200 μL of triethylamine to adjust the pH, shake well, then add 250 μL of the derivatization reagent di-tert-butyl dicarbonate, shake well, transfer to a conical flask, seal, and place in a 50°C water bath to react for 1 h.
[0173] 20 μL of each of the above derivatization solutions was injected into a liquid chromatograph for analysis, and the peak area of the derivatized product of the dimesylated enantiomer of lisdexamfetamine in the chromatogram was recorded. The results are shown in Table 5:
[0174] Table 5. Linearity test results
[0175]
[0176] Conclusion: The enantiomers of lisdexamfetamine dimesylate have good linearity in the range of 3.674μg / mL to 36.74μg / mL. The linear equation is: y=0.34x-0.1299, and the correlation coefficient is r=1.00.
[0177] Example 9 Quantitative Limit Test
[0178] The instrument and chromatographic conditions were the same as in Example 5.
[0179] Take 10 mL of the test sample stock solution in Example 5.2.2, add 50 μg of the dimethysulfonate enantiomer reference substance, add 200 μL of triethylamine to adjust the pH, add 250 μL of the derivatization reagent di-tert-butyl dicarbonate to carry out the derivatization reaction, shake well, place in a 50°C water bath to react for 1 h, and cool to obtain the product.
[0180] Take 20 μL of the above derivatization solution and inject it into the liquid chromatograph for detection and analysis. Inject 6 injections continuously and record the peak area of the chromatogram. The following results are obtained in Table 6:
[0181] Table 6. Quantitation limit verification results
[0182]
[0183] Conclusion: The quantitative limit solution was injected repeatedly for 6 times, and its signal-to-noise ratio S / N was greater than 10. The quantitative limit concentration was 0.00459 mg / mL, and the quantitative limit was 0.05%.
[0184] Example 10 Detection limit test
[0185] The instrument and chromatographic conditions were the same as in Example 5.
[0186] Take 10 mL of the test sample stock solution in the above Example 5.2.2, add 20 μg of the dimethysulfonate enantiomer reference substance, add 200 μL of triethylamine to adjust the pH, add 250 μL of the derivatization reagent di-tert-butyl dicarbonate, shake well, place in a 50°C water bath to react for 1 h, and cool to obtain the product.
[0187] 20 μL of the above derivatization solution was injected for analysis, and three injections were performed continuously. The peak area in the chromatogram was recorded to obtain the results in Table 7 below:
[0188] Table 7. Detection limit verification results
[0189] Serial number Signal-to-Noise Ratio 1 3.0 2 9.7 3 16.1 Detection limit concentration 0.00156mg / mL Detection limit 0.02%
[0190] Conclusion: The detection limit solution was injected three times repeatedly, and the signal-to-noise ratio S / N was ≥3. The detection limit concentration was 0.00156 mg / mL and the detection limit was 0.02%.
[0191] Example 11 Durability Test
[0192] Take 20 μL of the system suitability solution in Example 5.2.3 for sample injection and analysis, adjust the chromatographic conditions according to the following Table 8, and obtain the data results in Table 9:
[0193] Table 8. Durability Chromatographic Parameters
[0194]
[0195] Table 9. Durability verification results
[0196] name Enantiomeric separation original condition 1.5 Flow rate: 1.2 mL / min 1.4 Flow rate: 1.0 mL / min 1.5 Column temperature 38℃ 1.6 Column temperature 32℃ 1.4 Original mobile phase ratio 1.5 Mobile phase ratio 1 1.7 Mobile phase ratio 2 1.6 Mobile phase ratio 3 1.5 Mobile phase ratio 4 1.3 Replace the column with a different number 1.8 Replacement of different brands of chromatograph 1.5
[0197] Conclusion: After the standard conditions of durability and fine-tuning of chromatographic conditions to flow rates of 1.0 mL / min and 1.2 mL / min, column temperatures of 32 °C and 38 °C, fine-tuning of the mobile phase ratio, replacement of chromatographic columns, and replacement of chromatographs of different brands, the separation of enantiomers was greater than 1.3, which met the acceptable standards. The method has good durability.
[0198] Example 12 Normal Phase High Performance Liquid Chromatography Determination of Enantiomer Content in Dimesylate Lixamfetamine Product
[0199] 12.1. Main technical parameters of HPLC:
[0200] Instrument: Agilent 1260 high performance liquid chromatograph
[0201] Chromatographic conditions: Same as Example 5
[0202] 12.2. Sample configuration
[0203] 12.2.1 Test solution: Take three batches of 9A806011, 9A806021, and 9A806031 rexroxafenamide dimesylate capsules, take 10 capsules from each batch, pour out the contents and grind evenly in a mortar, weigh an appropriate amount of the ground powder (equivalent to approximately 200 mg of rexroxafenamide dimesylate), accurately weigh, place in a 25 mL volumetric flask, add 20 mL of methanol to dissolve by ultrasonication, and continue to dilute to the scale with methanol, shake well, centrifuge, take 5 mL of the upper clear liquid, add 100 μL of triethylamine to adjust the pH, and then add 125 μL of the derivatization reagent di-tert-butyl dicarbonate, and react in a 50°C water bath for 1 h as the test solution.
[0204] 12.2.2 Control solution: Take 100 μL of the test solution in 12.2.1 into a 10 mL volumetric flask, dilute to the mark with methanol, and shake well as the control solution.
[0205] 12.2.3 Sensitivity solution: Accurately measure 1.0 mL of the control solution in 12.2.2 into a 10 mL volumetric flask, dilute with methanol and make up to the mark, shake well, and the solution is ready.
[0206] Take 20 μL of the test solution, control solution and sensitivity solution for sample analysis, record the peak area in the chromatogram, and the test results are shown in Table 10.
[0207] Table 10. Test results of three batches
[0208] batch Enantiomer test results 9A806011 Not detected 9A806021 Not detected 9A806031 Not detected
[0209] Conclusion: No enantiomers were detected in the samples tested by this method, indicating that the content of the corresponding isomers did not exceed the limit (0.2%), and the three batches of samples in the instructions met the quality standard requirements. It provides corresponding guidance for whether there are isomers in the dimethoate amfetamine capsules.
[0210] The present application describes multiple embodiments, but the description is exemplary rather than restrictive, and it is obvious to a person skilled in the art that there may be more embodiments and implementations within the scope of the embodiments described in the present application.
Claims
1. A method for detecting enantiomers in lisdexamfetamine dimesylate, comprising the steps of: i) subjecting lisdexamfetamine dimethanesulfonate and its enantiomer to a derivatization reaction with a derivatization agent to obtain a derivatization product of lisdexamfetamine dimethanesulfonate and its enantiomer; ii) using normal phase high performance liquid chromatography to detect and analyze the derivatized product in step i) to separate and detect the derivatized dimesylated lisdexamfetamine and its enantiomers.
2. The method according to claim 1, in step i), the derivatization reaction can be carried out as follows: The dimethoate and enantiomers thereof are added into a solvent, dissolved by ultrasonication and filtered; Adding an alkaline regulator makes it alkaline; Add a derivatization reagent to carry out a derivatization reaction. After the reaction is completed, the mixture is cooled to room temperature to obtain a solution of a derivatized product of dimesylated amphetamine and its enantiomers.
3. The method according to claim 2, wherein the solvent is methanol; Optionally, the alkaline regulator is triethylamine or sodium hydroxide, preferably triethylamine; Optionally, the derivatization agent is a carboxylate, preferably di-tert-butyl dicarbonate; The derivatization reaction can be carried out in a water bath with heating at a temperature of 40-60° C. and a reaction time of more than 1 hour. Preferably, the reaction temperature is 50° C. and the reaction time is 1 hour.
4. The method according to claim 3, optionally, the concentration of the solution of lisdexamfetamine dimesylate and its enantiomers can be 10 mg / mL; Optionally, 200 μl of an alkaline regulator is added to every 10 ml of the solution of lisdexamfetamine dimesylate and its enantiomers; Optionally, 250 μl or more of a derivatizing agent is added to every 10 ml of the solution of lisdexamfetamine dimesylate and its enantiomers.
5. The method according to any one of claims 1 to 4, wherein in step ii), the chromatographic conditions of normal phase high performance liquid chromatography are: A chiral chromatographic column is used as a separation column, and the stationary phase is selected from polysaccharides. Preferably, the stationary phase is amylose-tris-(3-chloro-5-methylphenylcarbamate) covalently bonded to the surface of silica gel; Optionally, the mobile phase is a mixture of an organic solvent and an acid-base regulator in a volume ratio of 100:(0.05-0.15), preferably 100:0.1; Optionally, the acid-base regulator is an organic acid, preferably trifluoroacetic acid; Optionally, the organic solvent is a mixed solvent of n-hexane and lower alcohol in a volume ratio of (85-90):(10-15), preferably 90:10; Optionally, the lower alcohol is selected from one or both of methanol and ethanol, preferably, the lower alcohol is a combination of methanol and ethanol; Preferably, the volume ratio of each component in the organic solvent is n-hexane:methanol:ethanol is 90:2.5:7.
5.
6. The method according to claim 5, wherein the other conditions of the normal phase high performance liquid chromatography are include: The chromatographic column is CHIRALPAK IG, 4.6×250 mm; 5 μm; The detection wavelength is 200-400 nm, preferably 210 nm; The injection volume was 20 μL; The flow rate is 1.0-1.2 mL / min, preferably 1.1 mL / min; The column temperature is 32°C-38°C, preferably 35°C; Isocratic elution.
7. A method for detecting enantiomers in a rexroximate dimesylate preparation, comprising derivatizing the rexroximate dimesylate preparation according to the method described in any one of claims 1 to 6, and performing qualitative and quantitative analysis of the enantiomers contained in the rexroximate dimesylate preparation by normal phase high performance liquid chromatography under the chromatographic conditions described in any one of claims 1 to 6; comprising the following steps: S100: Preparation of solution S101: Preparation of reference substance solution: prepare stock solutions of dixamfetamine dimesylate and its enantiomer reference substance respectively, and carry out derivatization reaction with derivatization reagents respectively to obtain reference substance solutions a of dixamfetamine dimesylate and its enantiomer 1 and a 2 ; S102: preparing a test solution: preparing a test stock solution of the dixamfetamine dimesylate preparation and subjecting it to a derivatization reaction with a derivatization reagent to obtain a test solution; S103: Prepare a control solution: dilute the test solution in step S102 to obtain a control solution; S200: Detection For the reference solution a in step S101 1 and a 2 , the test solution in S102 and the control solution in S103 are tested and the chromatograms are recorded; S300: Analysis Determine the retention time of the derivatized product of dimesymphetamine and its enantiomers according to the chromatogram of the reference solution; The content of the enantiomer in the test sample was calculated by the self-control method based on the peak area of the derivatized product of the dimethoate enantiomer in the chromatograms of the test solution and the control solution.
8. according to the method described in claim 7, in step S101, dimethysulfate lisdexamfetamine reference substance solution a 1 and its enantiomer reference solution a 2 The preparation method is as follows: Lixamfetamine dimesylate reference solution a 1 :The reference substance of dimethoate is dissolved in a solvent to a fixed volume, and the reference substance of dimethoate is obtained as a stock solution. in, Optionally, the concentration of the reference substance stock solution of dimethylate is 10 mg / mL; a portion of the reference substance stock solution of dimethylate is transferred, an alkaline regulator is added until it becomes alkaline, and a derivatization reaction is carried out with a derivatization reagent to obtain a reference substance solution of dimethylate. 1 ; Enantiomer reference solution a 2 : dissolving the dimethoxyamphetamine dimethanesulfonate enantiomer reference substance in a solvent to obtain a dimethoxyamphetamine dimethanesulfonate enantiomer reference substance stock solution, wherein, optionally, the concentration of the dimethoxyamphetamine dimethanesulfonate enantiomer reference substance stock solution is 1 mg / mL; taking a portion of the dimethoxyamphetamine dimethanesulfonate enantiomer reference substance stock solution, adding an alkaline regulator until it is alkaline, and performing a derivatization reaction with a derivatization reagent to obtain a dimethoxyamphetamine dimethanesulfonate enantiomer reference substance solution a 2 ; In step S102, the preparation method of the test solution is as follows: The dixamfetamine dimethanesulfonate preparation is dissolved in a solvent and filtered, and the filtrate is taken as a test sample stock solution, wherein the concentration of the dixamfetamine dimethanesulfonate test sample stock solution is 10 mg / mL; a portion of the test sample stock solution is transferred, an alkaline regulator is added to make it alkaline, and a derivatization reaction is carried out with a derivatization reagent to obtain the test sample solution.
9. The method according to claim 8, wherein optionally, the lisdexamfetamine dimesylate preparation is a capsule preparation.
10. The method according to any one of claims 7 to 9, in step S300, the calculation formula for the enantiomer content in the test sample is:
